QGEN Stock - Qiagen N.V.
Unlock GoAI Insights for QGEN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.98B | $1.97B | $2.14B | $2.25B | $1.87B |
| Gross Profit | $967.35M | $1.23B | $1.38B | $1.45B | $1.23B |
| Gross Margin | 48.9% | 62.8% | 64.7% | 64.4% | 65.9% |
| Operating Income | $97.71M | $409.94M | $531.46M | $630.08M | $386.43M |
| Net Income | $83.59M | $341.30M | $423.21M | $512.60M | $359.19M |
| Net Margin | 4.2% | 17.4% | 19.8% | 22.8% | 19.2% |
| EPS | $0.39 | $1.54 | $1.92 | $2.32 | $0.33 |
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Citigroup | Downgrade | Neutral | $50 |
| June 24th 2025 | Barclays | Initiation | Overweight | $55 |
| April 4th 2025 | Redburn Atlantic | Downgrade | Neutral | - |
| February 19th 2025 | Robert W. Baird | Downgrade | Neutral | $42← $52 |
| January 6th 2025 | Morgan Stanley | Downgrade | Equal Weight | $48 |
| December 10th 2024 | Jefferies | Upgrade | Buy | $54← $42.5 |
| October 17th 2024 | HSBC Securities | Downgrade | Hold | $49 |
| June 27th 2024 | Wolfe Research | Upgrade | Outperform | $50 |
| December 19th 2023 | Wells Fargo | Initiation | Equal Weight | $44 |
| December 13th 2023 | Wolfe Research | Initiation | Peer Perform | - |
| December 7th 2023 | Goldman | Upgrade | Buy | $50 |
| September 12th 2023 | Robert W. Baird | Initiation | Outperform | $50 |
| May 23rd 2023 | Morgan Stanley | Upgrade | Overweight | - |
| October 18th 2022 | Morgan Stanley | Initiation | Equal Weight | - |
Earnings History & Surprises
QGENEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $0.59 | — | — | — |
Q4 2025 | Nov 4, 2025 | $0.58 | $0.61 | +5.2% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.60 | $0.60 | 0.0% | = MET |
Q2 2025 | May 7, 2025 | $0.50 | $0.55 | +9.3% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $0.60 | $0.61 | +1.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $0.54 | $0.57 | +5.6% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $0.53 | $0.57 | +7.5% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $0.44 | $0.46 | +4.5% | ✓ BEAT |
Q1 2024 | Feb 6, 2024 | $0.55 | $0.55 | 0.0% | = MET |
Q4 2023 | Oct 30, 2023 | $0.52 | $0.53 | +1.9% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.53 | $0.54 | +1.9% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $0.50 | $0.54 | +8.0% | ✓ BEAT |
Q1 2023 | Feb 7, 2023 | $0.50 | $0.56 | +12.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $0.48 | $0.56 | +16.7% | ✓ BEAT |
Q3 2022 | Jul 26, 2022 | $0.46 | $0.51 | +10.9% | ✓ BEAT |
Q2 2022 | Apr 26, 2022 | $0.73 | $0.80 | +9.6% | ✓ BEAT |
Q1 2022 | Feb 8, 2022 | $0.60 | $0.74 | +23.3% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $0.53 | $0.58 | +9.4% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.65 | $0.67 | +3.1% | ✓ BEAT |
Latest News
QIAGEN Shares To Begin Trading On January 8, 2026, Post-Reverse Stock Split On NYSE And Frankfurt Exchange
➖ NeutralQIAGEN To Return $500M To Shareholders Through Synthetic Share Repurchase And Reverse Stock Split; Every 20 Issued QIAGEN Shares Will Be Consolidated Into 19 QIAGEN Shares, Leading To A Reduction Of ~10.9M Shares From The Level Of 217.7M Shares
📈 PositiveBarclays Maintains Overweight on Qiagen, Raises Price Target to $55
📈 PositiveCitigroup Downgrades Qiagen to Neutral, Lowers Price Target to $50
📉 NegativeQIAGEN Launches QIAsymphony Connect For Liquid Biopsy Workflows And Highlights HRD And CGP Innovations At AMP 2025
📈 PositiveUpdate: Qiagen Raises FY2025 Adj EPS Guidance from $2.35 to $2.38 vs $2.37 Est; Affirms FY2025 Sales Guidance of $2.057B-$2.077B vs $2.082B Est
➖ NeutralQiagen Sees Q4 Adj EPS $0.60 vs $0.61 Est
📉 NegativeQiagen N.V. Shares Resume Trade
➖ NeutralCORRECTION: QIAGEN Acquires Parse Biosciences For ~$225M
➖ NeutralQiagen Raises FY2025 Adj EPS Guidance from $2.35 to $2.38 vs $2.37 Est
📈 PositiveQIAGEN Announces Plans To Complete A $500M Synthetic Share Repurchase In Early January 2026
📈 PositiveQiagen Q3 Adj. EPS $0.61 Beats $0.59 Estimate, Sales $533.000M Beat $525.929M Estimate
📈 PositiveQIAGEN CEO Thierry Bernard To Step Down After Successor Is Named
➖ NeutralQIAGEN Signs Agreement To Acquire Parse Biosciences For Upfront Payment Of ~$225M In Cash; Parse Shareholders Entitled For Additional Milestone Payments Of Up To $55M
📈 PositiveQIAGEN Launches Automated EZ2 DNA Investigator Sep&Prep Kit To Automate Sexual Assault Sample Processing And Enhance Forensic DNA Recovery
📈 PositiveQiagen Obtains CE-IVDR Certification For Its Full Portfolio Of Qiastat-Dx Syndromic Testing Systems And Panels
📈 PositiveQIAGEN Expands QIAstat-Dx Portfolio In US With FDA Clearance Of Rise For Rapid Infectious Disease Diagnostics
📈 PositiveFrequently Asked Questions about QGEN
What is QGEN's current stock price?
What is the analyst price target for QGEN?
What sector is Qiagen N.V. in?
What is QGEN's market cap?
Does QGEN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to QGEN for comparison